Back to Directory
Fremanezumab
Performance & EnduranceAnti-CGRP monoclonal antibody for migraine prevention, monthly or quarterly injections.
Key Benefits
- ✓Prevents migraines
- ✓Monthly or quarterly dosing
- ✓Reduces migraine days
- ✓Subcutaneous injection
- ✓Alternative to daily pills
Dosing Information
Dosage Range
225-675 mg
Frequency
Monthly or quarterly
Typical Duration
Ongoing
Detailed Protocol
Administered via subcutaneous injection monthly (225mg) or quarterly (675mg). Can be self-administered or given in office. Prescription required.
About Fremanezumab
Fremanezumab (Ajovy) is a humanized monoclonal antibody that binds to CGRP ligand, preventing migraine. Available as monthly or quarterly subcutaneous injection. FDA-approved for migraine prevention.
Research Notes
FDA-approved in 2018 for migraine and cluster headache prevention. Flexible dosing (monthly or quarterly). Well-tolerated with few side effects. Standard migraine preventive option.
Potential Side Effects
- •Injection site reactions
- •Hypersensitivity
- •Generally well tolerated
- •Minimal side effects
Always consult with a healthcare professional before starting any peptide therapy.